Apolipoprotein levels in patients with Acute Coronary Syndrome (LIPAS): A pilot study
- Author:
Elleen L. Cunanan
1
;
John Daniel A. Ramos
1
;
Mariel I. Barcelon-Cruz
1
;
Elmer Jasper B. Llanes
2
;
Felix Eduardo R. Punzalan
2
;
Paul Ferdinand M. Reganit
2
;
Lourdes Ella G. Santos
2
;
Rody G. Sy
2
;
Jezreel L. Taquiso
1
Author Information
- Publication Type:Journal Article
- Keywords: Lipas
- MeSH: Acute Coronary Syndrome; Apolipoproteins
- From: Philippine Journal of Internal Medicine 2018;56(2):56-61
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Lowering levels of low-density lipoprotein cholesterol (LDL-C) are proven to reduce cardiovascular risk. However, some individuals experience acute coronary events despite normal LDL-C levels. Recent studies have focused on modifiable lipoprotein targets, such as apolipoprotein B (apo-B) and apolipoprotein A-1 (apo A-1) and lipoprotein (a), as targets for therapy. Apo-B is the primary apolipoprotein of LDL-C representing total number of atherogenic particles. Apolipoprotein A-1 is the major component of HDL complex. This study will determine the prevalence of elevated apo-B and low apo A-1 among adult Filipinos with acute coronary syndrome (ACS).
Methods:This is a cross-sectional study involving 95 patients with ACS admitted in a tertiary hospital from November 2015 to May 2016. Levels of apo-B, apoA-1, lipoprotein (a), total cholesterol, triglyceride, LDL-C, and high-density lipoprotein cholesterol (HDL-C) were measured within 24 hours upon admission.
Results:Forty-eight (48%) percent of patients was diagnosed with Non ST-Elevation-ACS, 39% with ST-Elevation myocardial infarction (STEMI) and 13% with unstable angina.Thirtytwo (32%) percent were on low- to high-intensity statin treatment. The mean LDL-C, non-HDL-C, and HDL-C levels were 109 mg/dL, 135 mg/dL, and 36.89 mg/dL, respectively. The prevalence of elevated apo-B (mean=103.79 mg/ dL; target:<80 mg/dL) was 82%, while that of low apo A-1 (mean=119 mg/dL; target: >120 mg/dL for males, >140 mg/dL for females) was 63%. Lipoprotein (a) levels are high (mean = 48.51 nmol/L; normal:<35 nmol/L) in 42% of patients. Among those on statin therapy, the mean LDL-C was 85 mg/dl, but the mean apo B and lipoprotein (a) levels were elevated at 87.57 mg/dL and 41 nmol/L, respectively.
Conclusion:Elevated levels of apo B and lipoprotein (a) and low level of apo A-1 are highly prevalent in patients with ACS. Apo-B and lipoprotein (a) levels are likewise elevated among patients with normal LDL levels. - Full text:FINAL_2017-054_Apolipoprotein.pdf
